Publicaciones en colaboración con investigadores/as de Free University of Berlin (15)

2020

  1. Paediatric population pharmacokinetic modelling to assess hydrocortisone replacement dosing regimens in young children

    European Journal of Endocrinology, Vol. 183, Núm. 4, pp. 357-368

  2. Pharmacokinetic/Pharmacodynamic evaluation of hydrocortisone therapy in pediatric patients with congenital adrenal hyperplasia

    Journal of Clinical Endocrinology and Metabolism, Vol. 105, Núm. 4, pp. E1729-E1740

  3. Response to 'Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia'

    European Journal of Endocrinology

2019

  1. The circadian rhythm of corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone dosing

    Clinical Endocrinology, Vol. 91, Núm. 1, pp. 33-40

2018

  1. Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients

    Clinical Pharmacokinetics, Vol. 57, Núm. 2, pp. 229-242

  2. Predicting Cortisol Exposure from Paediatric Hydrocortisone Formulation Using a Semi-Mechanistic Pharmacokinetic Model Established in Healthy Adults

    Clinical Pharmacokinetics, Vol. 57, Núm. 4, pp. 515-527

2017

  1. Making use of modeling and simulations: Towards individualized tamoxifen therapy in breast cancer

    International Journal of Clinical Pharmacology and Therapeutics

  2. Model description language (MDL): A standard for modeling and simulation

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 6, Núm. 10, pp. 647-650

  3. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment

    Basic and Clinical Pharmacology and Toxicology, Vol. 121, Núm. 4, pp. 309-315

  4. Semimechanistic bone marrow exhaustion pharmacokinetic/pharmacodynamic model for chemotherapy-induced cumulative neutropenia

    Journal of Pharmacology and Experimental Therapeutics, Vol. 362, Núm. 2, pp. 347-358

2016

  1. Utilising the EGFR interactome to identify mechanisms of drug resistance in non-small cell lung cancer – Proof of concept towards a systems pharmacology approach

    European Journal of Pharmaceutical Sciences, Vol. 94, pp. 20-32

2015

  1. Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Relationships of Monoclonal Antibodies in Children

    Clinical Pharmacokinetics, Vol. 54, Núm. 1, pp. 35-80

  2. Pharmacometrics Markup Language (PharmML): Opening new perspectives for model exchange in drug development

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 4, Núm. 6, pp. 316-319

2014

  1. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis

    CPT: Pharmacometrics and Systems Pharmacology, Vol. 3, Núm. 5

2005

  1. Novel Cu(II) quinoxaline N1,N4-dioxide complexes as selective hypoxic cytotoxins

    European Journal of Medicinal Chemistry, Vol. 40, Núm. 5, pp. 473-480